Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma

NCT02697552 is registered in ClinicalTrials.gov with HUYABIO International, LLC. as lead sponsor.

NCT NCT02697552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02697552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma
Lead sponsor
HUYABIO International, LLC.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2014
Completion date
October 31, 2016
Enrollment
13 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma